Physician profile
Nicholas Mayfield
NPI 1467479089
$4,734.82
in general payments reported to CMS, 2019-2025
18 companies · $1,199 in 2025
The $1,199 reported for 2025 was more than what 81% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $551 · 2020: $237 · 2021: $473 · 2022: $590 · 2023: $653 · 2024: $1,032 · 2025: $1,199.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,884.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,883.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $1,329.83 | 2019-2025 | Eylea Hd, Eylea |
| Genentech USA, INC. | $573.20 | 2019-2025 | Vabysmo, Lucentis, Susvimo |
| Alimera Sciences, INC. | $539.35 | 2019-2024 | Iluvien, Yutiq |
| Apellis Pharmaceuticals, INC. | $397.83 | 2022-2025 | Syfovre |
| Allergan, INC. | $382.82 | 2019-2021 | |
| Abbvie INC. | $236.72 | 2022-2025 | |
| Astellas Pharma US INC | $224.12 | 2024-2025 | Izervay |
| Alcon Vision LLC | $189.55 | 2021-2024 | Lensx, Constellation |
| Ani Pharmaceuticals, INC. | $189.50 | 2024-2025 | Purified Cortrophin Gel, Iluvien, Yutiq |
| Tarsus Pharmaceuticals, INC. | $182.73 | 2024-2025 | Xdemvy |
| Novartis Pharmaceuticals Corporation | $172.65 | 2019-2021 | |
| Glaukos Corporation | $120.33 | 2025 | Idosetr |
| Genentech, INC. | $57.72 | 2021-2022 | |
| Amgen INC. | $46.77 | 2024 | Tepezza |
| Rxsight INC | $40.79 | 2025 | Light Adjustable Lens (Lal), Rxsight Injector Handpiece, Rxsight Light Delivery Device (Ldd) |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $18.90 | 2024 | Xiidra, Miebo |
| Zimmer Biomet Holdings, INC. | $18.34 | 2023 | Sternalock Blu System |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $13.67 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nicholas Mayfield listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.